Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Koninklijke Philips NV (PHG) Price & Performance

Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Koninklijke Philips NV — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Koninklijke Philips NV trades at $26.79 (market cap $26.58B). The key difference: GSK plc is far larger — about 3.9× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.

GSKPHG
Market Cap
$102.60B$26.58B
Sector
HealthHealth
52-Week High
$61.18$32.91
52-Week Low
$38.22$25.02
Enterprise Value
$123.04B$33.13B
Dividend Yield
3.57%3.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Koninklijke Philips NV

PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.

The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG